Immunomedics, Barbara Duncan
After a turbulent period and looking to strengthen its leadership, Immunomedics appointed Barbara Duncan to its board of directors and chairperson of the audit committee.
Alongside her place at Immunomedics, Duncan will balance the role alongside her position as board member of five companies, holding roles at ObsEva, Aevi Genomic Medicine, Adaptimmune Therapeutics, Jounce Therapeutics, and Ovid Therapeutics.
The appointment arrived two weeks after the biotech’s CEO, Michael Pehl, stepped down from his position at the company.
Alongside the announcement of the departure of its CEO, the company also acknowledged it had received a complete response letter (CRL) from the US Food and Drug Administration (FDA) to its biologics license application for sacituzumab govitecan. The manufacturing issues were revealed to be related to data integrity breaches in the FDA’s inspection report.
Pehl had only been in the position of CEO for 15 months at the time of his leaving, which arrived a few weeks after the FDA’s inspection was made public.
At the same time as announcing Pehl’s departure, the company also announced that Scott Canute had joined the company’s board as executive director – highlighting his experience as president of global manufacturing and corporate operations at Genzyme.
Immunomedics has not yet announced a replacement for Pehl.